Note: Articles may be assigned to more than one subject area, as a result the sum of the subject research outputs may not equal the overall research outputs. Note: Hover over the donut graph to view ...

When Kiersten McCartney was 5 years old, her best friend’s father sustained a life-changing spinal cord injury. “As a kid, I never saw Peter as limited. He always tells people that wheelchair ...

Mr. Kaushal will be responsible for the implementation of the Company's strategy to become a full service provider to the healthcare industry. Mr. Kaushal brings more than 25 years of financial and ...

EDMONTON, AB, May 3 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), today announced its updated corporate strategy. The Company's new strategy will encompass ...

EDMONTON, April 30 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), today announced that the University of Alberta, a major shareholder of the Company, has ...

EDMONTON, March 16 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), today announced financial and operational results for the year ended December 31, 2009 ...

How many athletes do you know who run with a yak? Aside from being a conversation starter, the unusual choice of yak leather that Ecco is using for its high-end running shoes helps drum home the idea ...

The Company has completed its substantive review of the data from the discontinued late-stage trials for dirucotide, its drug candidate for the treatment of multiple sclerosis (MS). BioMS has decided ...

Eli Lilly and partner BioMS Medical Corp‘s dirucotide has failed a late-stage trial as a potential treatment for multiple sclerosis. Eli Lilly and partner BioMS Medical Corp‘s dirucotide has failed a ...

Dirucotide did not meet endpoints in one of three Phase III studies in secondary progressive multiple sclerosis. Eli Lilly and BioMS Medical are halting development of the latter’s multiple sclerosis ...